Welcure Drugs and Pharmaceuticals Limited (hereinafter referred to as 'The Company' or 'WDPL') was incorporated as a Public Limited Company under the Companies Act, 1956 on 4th June, 1992 and obtained the certificate of commencement of business on 19th June 1992. The registered office of the Company is situated at E-1052. Saraswati Vihar, Delhi - 110 034. PRESENT BUSINESS Presently, the Company is engaged in the business of manufacture and marketing of pharmaceuticals formulations in the form of tablets, capsules and dry syrups. The Company is manufacturing over hundred varieties of formulations including antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarials, anti-dysentery, anti-tuberculosis, anti-diabetics, tranquilisers, sedatives and gastro intestinals. The products of the company have already been well accepted in the domestic markets and the Company has an established customer base. SWOT ANALYSIS Strengths 1. One of the Promoters is having over two decades and the other two promoters are having over a decade experience in the pharmaceutical industry. 2. The Plant & Machinery taken by the company is a multipurpose plant on which other drugs can be produced apart from what company intends to manufacture. 3. The technolgy required to manufacture of the drugs is indegenously available. 4. Approval of first floor of factory by Drugs Control Department to systematically and properly utilise the space for expanded capacity. 5. Major portion of bulk drugs will be used for captive consumption for manufacture of pharmaceuticals formulations. 6. With the completion of the bulk drug unit, the Company will have integrated facilities to manufacture intermediates, bulk drugs and formulations. 7. Subsidiary Company A.K.Laboratories Ltd. is producing 6 APA, a critical drug intermediate used for manufacture of life saving antibiotic drugs like viz. Ampicillin, Amoxycillin, Cloxacillin and Cephalexin. Weaknesses 1. Commercial production of the existing formulation unit was delayed by five months and bulk drug unit is expected to be delayed by approximately 18 months. 2. The cost of the project and means of finance have not been appraised by any Bank/Financial Institution. 3. Delay in Government approvals may affect the timely implementation of the project. Opportunities 1. Products have a growing domestic market and good export potential. Threats 1. Competition from existing and proposed manufacturers as is normal and prevalent in any industry. 2. Changes in Drug Policy announced by the Government from time to time may have an impact on the operations of the Company. 2008 -Welcure Drugs & Pharmaceuticals Ltd has designated E-mail ID for Investors Complaints - welcure@gmail.com.